US OptionsDetailed Quotes

BWAY250117P17500

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Jaguar8
    Jaguar8
    Dec 12 07:01
    NEWS
    $Brainsway (BWAY.US)$
    BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
    Thursday, 12th December at 8:00 am
    BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in the advanced non-invasive treatment of brain disorders, today announced recent positive pilot data from an independent, third-party study conducted at Stanford University evalua...
    Jaguar8
    Jaguar8
    Nov 20 07:06
    NEWS
    $Brainsway (BWAY.US)$
    BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
    BrainsWay (NASDAQ & TASE: BWAY) announced positive feasibility clinical data for their Deep TMS™ therapy in treating peripheral neuropathic pain. The double-blind, randomized crossover trial involved 17 patients who received either active Deep TMS or sham treatment for five days, followed by a nine-week washout period before switching treatments. Results demonstrated significant r...
    Jaguar8
    Jaguar8
    Jun 17 06:37
    NEWS
    $Brainsway (BWAY.US)$
    BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada
    BrainsWay has announced an exclusive multi-year distribution agreement to market its Deep Transcranial Magnetic Stimulation (Deep TMS) system in Canada. The agreement involves a specialty distributor serving acute and non-acute healthcare sectors, and includes minimum quantity orders, starting with 11 systems in 2024. BrainsWay’s CEO, Hadar Levy, emphasized the significance of exp...
    Jaguar8
    Jaguar8
    Jun 3 06:35
    NEWS
    $Brainsway (BWAY.US)$
    BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression
    BrainsWay has announced that the FDA has expanded the indication for its Deep Transcranial Magnetic Stimulation system (Deep TMS™) to treat major depressive disorder (MDD) in patients aged 22 to 86, extending beyond the previous age limit of 68. This marks the company's 10th FDA clearance, making their Deep TMS the only TMS device approved for depression treatment in patients over 68. The expanded lab...
    Stock Region
    Stock Region
    Mar 28 17:48
    Medical Technology Company Reveals Promising Outcomes For Depression Treatment
    A Glimmer of Hope: Revolutionizing Late-Life Depression Treatment with Deep TMS Technology.
    Depression is a formidable adversary at any age, but it poses unique challenges for the elderly. Traditional treatments often fall short, leaving a gap that demands innovative solutions. Enter Deep Transcranial Magnetic Stimulation (Deep TMS) technology, a beacon of hope for those battling late-life depression. Recent findings f...
Read more